A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Lack of Tocilizumab effect on mortality in COVID19 patients
[post]
2020
unpublished
Preserved Fulltext
Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration. Correlating mortality with increased IL-6 doesn't imply causality however lack of improvement by tocilizumab requires clinical trial alterations.
doi:10.21203/rs.3.rs-39875/v1
fatcat:dklxtsesvnfstmjbovs25juvue